Business
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014\n \n \nMarina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014\n\nSMARTICLES(R) Formulated PNT2258 Achieved Meaningful Therapeutic Outcomes\n\n \n BOTHELL, WA--(Marketwired - Dec 9, 2014) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, reported that a number of patients with relapsed or refractory Non-Hodgkin's Lymphoma treated with its first DNAi®-based therapeutic, PNT2258, achieved meaningful therapeutic outcomes and continue to exhibit durable clinical responses. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES® delivery technology.\n The interim results from the ongoing pilot Phase II trial of PNT2258, a DNAi-based therapeutic targeting BCL2, were reported in a poster entitled: \"The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma\" at the 56th Annual Meeting of the American Society of Hematology (ASH), being held in San Francisco. The investigators for the study concluded that:\n \n \n PNT2258 treatment results in significant, durable responses in patients with relapsed or refractory non-Hodgkin's Lymphoma (r/r NHL);\n \nEleven of the thirteen (11/13) patients treated achieved clinical benefit, with ongoing Progression Free Survival (PFS) extending to 18 months and beyond;\n \nPNT2258 is demonstrably active in patients with diffuse large B-cell lymphoma (DLBCL). All four of the patients (4/4) with DLBCL responded to PNT2258, with three patients achieving complete responses (CR) and one patient achieving a partial response (PR), with durations extending to greater than 500 days;\n \nDurable and clinically meaningful CR's and PR's were achieved in subjects with aggressive disease, such as Richter's transformation and Burkitt's-like DLBCL;\n \nNoteworthy durable CR's and PR's were also observed in subjects with advanced stage follicular lymphoma (FL); and\n \nPNT2258 th...